229 related articles for article (PubMed ID: 36604351)
1. Comparison of breast cancer HER-2 receptor testing with immunohistochemistry and in situ hybridization.
Shanmugalingam A; Hitos K; Pathmanathan N; Edirimmane S; Hughes TM; Ngui NK
Breast Cancer Res Treat; 2023 Feb; 198(1):143-148. PubMed ID: 36604351
[TBL] [Abstract][Full Text] [Related]
2. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
3. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
4. Reflex Repeat HER2 Testing of Grade 3 Breast Carcinoma at Excision Using Immunohistochemistry and In Situ Analysis: Frequency of HER2 Discordance and Utility of Core Needle Biopsy Parameters to Refine Case Selection.
Prendeville S; Feeley L; Bennett MW; O'Connell F; Browne TJ
Am J Clin Pathol; 2016 Jan; 145(1):75-80. PubMed ID: 26712873
[TBL] [Abstract][Full Text] [Related]
5. The impact of 2018 ASCO-CAP HER2 testing guidelines on breast cancer HER2 results. An audit of 2132 consecutive cases evaluated by immunohistochemistry and in situ hybridization.
Farshid G; Dhatrak D; Gilhotra A; Koszyca B; Nolan J
Mod Pathol; 2020 Sep; 33(9):1783-1790. PubMed ID: 32366941
[TBL] [Abstract][Full Text] [Related]
6. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
7. Impact of the 2018 ASCO/CAP guidelines on HER2 fluorescence in situ hybridization interpretation in invasive breast cancers with immunohistochemically equivocal results.
Wang B; Ding W; Sun K; Wang X; Xu L; Teng X
Sci Rep; 2019 Nov; 9(1):16726. PubMed ID: 31723206
[TBL] [Abstract][Full Text] [Related]
8. Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study.
Hanna WM; Barnes PJ; Chang MC; Gilks CB; Magliocco AM; Rees H; Quenneville L; Robertson SJ; SenGupta SK; Nofech-Mozes S
J Clin Oncol; 2014 Dec; 32(35):3967-73. PubMed ID: 25385731
[TBL] [Abstract][Full Text] [Related]
9. Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
Solomon JP; Dell'Aquila M; Fadare O; Hasteh F
Am J Clin Pathol; 2017 Apr; 147(4):432-437. PubMed ID: 28340220
[TBL] [Abstract][Full Text] [Related]
10. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
Bethune GC; Pettit AS; Veldhuijzen van Zanten D; Barnes PJ
Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
[TBL] [Abstract][Full Text] [Related]
11. HER2 double-equivocal breast cancer in Chinese patients: a high concordance of HER2 status between different blocks from the same tumor.
Liu Y; Wu S; Shi X; Luo Y; Pang J; Wang C; Mao F; Liang Z; Zeng X
Breast Cancer Res Treat; 2019 Nov; 178(2):275-281. PubMed ID: 31388934
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Accuracy of Immunohistochemistry for HER2-Positive Breast Cancer.
Thanasan S; Sukhakul K; Chitpakdee S; Kitkumthorn N
Asian Pac J Cancer Prev; 2023 Dec; 24(12):4321-4327. PubMed ID: 38156869
[TBL] [Abstract][Full Text] [Related]
13. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Wolff AC; Hammond ME; Hicks DG; Dowsett M; McShane LM; Allison KH; Allred DC; Bartlett JM; Bilous M; Fitzgibbons P; Hanna W; Jenkins RB; Mangu PB; Paik S; Perez EA; Press MF; Spears PA; Vance GH; Viale G; Hayes DF; ;
Arch Pathol Lab Med; 2014 Feb; 138(2):241-56. PubMed ID: 24099077
[TBL] [Abstract][Full Text] [Related]
14. What to expect from the 2018 ASCO/CAP HER2 guideline in the reflex in situ hybridization test of immunohistochemically equivocal 2+ cases?
Curado M; Caramelo AS; Eloy C; Polónia A
Virchows Arch; 2019 Sep; 475(3):303-311. PubMed ID: 30953146
[TBL] [Abstract][Full Text] [Related]
15. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study.
Lim TH; Lim AST; Tien SL; Tan PH
Ann Diagn Pathol; 2022 Jun; 58():151935. PubMed ID: 35313158
[TBL] [Abstract][Full Text] [Related]
16. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
17. UK recommendations for HER2 assessment in breast cancer: an update.
Rakha EA; Tan PH; Quinn C; Provenzano E; Shaaban AM; Deb R; Callagy G; Starczynski J; Lee AHS; Ellis IO; Pinder SE
J Clin Pathol; 2023 Apr; 76(4):217-227. PubMed ID: 36564170
[TBL] [Abstract][Full Text] [Related]
18. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
19. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
[TBL] [Abstract][Full Text] [Related]
20. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]